Immunic, Inc. (IMUX)
Largest Insider Buys in Sector
IMUX Stock Price History Chart
IMUX Stock Performance
About Immunic, Inc.
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the …
Insider Activity of Immunic, Inc.
Over the last 12 months, insiders at Immunic, Inc. have bought $118,702 and sold $0 worth of Immunic, Inc. stock.
On average, over the past 5 years, insiders at Immunic, Inc. have bought $131,809 and sold $205,490 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rudick Richard Alan (director) — $100,369. Vitt Daniel (President and CEO) — $18,333.
The last purchase of 87,300 shares for transaction amount of $100,369 was made by Rudick Richard Alan (director) on 2024‑11‑12.
List of Insider Buy and Sell Transactions, Immunic, Inc.
| 2024-11-12 | director | 87,300 0.0969% | $1.15 | $100,369 | -6.96% | |||
| 2024-02-26 | President and CEO | 14,000 0.0159% | $1.31 | $18,333 | +3.91% | |||
| 2023-05-15 | Chief Financial Officer | 5,000 0.0114% | $1.75 | $8,750 | -22.16% | |||
| 2022-12-14 | director | 47,000 0.1472% | $1.26 | $59,032 | +28.97% | |||
| 2022-12-13 | director | 35,000 0.1105% | $1.25 | $43,610 | +31.05% | |||
| 2022-11-23 | director | 18,000 0.0578% | $1.39 | $25,020 | +19.85% | |||
| 2022-11-22 | President and CEO | 8,000 0.0259% | $1.35 | $10,799 | +24.05% | |||
| 2022-11-07 | Chief Financial Officer | 5,000 0.0164% | $1.50 | $7,475 | +13.64% | |||
| 2022-06-03 | President and CEO | 5,000 0.0151% | $3.10 | $15,500 | -43.22% | |||
| 2022-06-03 | Chief Financial Officer | 3,500 0.0104% | $3.04 | $10,658 | -43.22% | |||
| 2022-05-12 | Chief Medical Officer | 3,500 0.0115% | $5.10 | $17,850 | -59.81% | |||
| 2022-05-12 | Executive Chairman | 10,000 0.0323% | $5.03 | $50,300 | -59.81% | |||
| 2022-05-12 | Chief Financial Officer | 3,000 0.0098% | $5.08 | $15,240 | -59.81% | |||
| 2021-08-10 | President and CEO | 1,000 0.0039% | $9.60 | $9,600 | -5.42% | |||
| 2021-08-10 | Executive Chairman | 1,000 0.004% | $9.80 | $9,800 | -5.42% | |||
| 2021-08-10 | PFO and PAO | 1,500 0.006% | $9.85 | $14,775 | -5.42% | |||
| 2021-05-12 | Executive Chairman | 4,000 0.0186% | $12.75 | $51,000 | -21.89% | |||
| 2021-03-02 | Chief Medical Officer | 10,006 0.046% | $15.54 | $155,493 | -34.17% | |||
| 2021-03-02 | PFO and PAO | 1,000 0.0049% | $16.48 | $16,480 | -34.17% | |||
| 2020-08-10 | PFO and PAO | 1,000 0.0051% | $18.96 | $18,960 | -20.03% |
Insider Historical Profitability
| Vitt Daniel | President and CEO | 390877 0.4339% | $1.11 | 4 | 2 | <0.0001% |
| Rudick Richard Alan | director | 87300 0.0969% | $1.11 | 1 | 0 | |
| Muehler Andreas | Chief Medical Officer | 297986 0.3308% | $1.11 | 2 | 0 | <0.0001% |
| Winters Terence E. | Co-Chairman and CEO | 194966 0.2164% | $1.11 | 2 | 0 | +75.81% |
| Neermann Joerg | director | 100000 0.111% | $1.11 | 3 | 0 | +26.62% |
Institutional Investor Ownership
| Bvf Inc Il | $11.75M | 9.88 | 8.9M | New | +$11.75M | 0.09 | |
| Avidity Partners Management Lp | $11.75M | 9.88 | 8.9M | New | +$11.75M | 0.45 | |
| Soleus Capital Management, L.P. | $9.63M | 8.1 | 7.29M | +2,331% | +$9.23M | 0.04 | |
| Janus Henderson | $9.27M | 7.76 | 6.99M | New | +$9.27M | 0.01 | |
| Adage Capital Partners Gp L L C | $7.38M | 6.21 | 5.59M | New | +$7.38M | 0.01 |